Big Pharma China Roundup: Roche Struggles, GSK Rebounds
This article was originally published in PharmAsia News
Executive Summary
Despite big pharma firms generally accelerating growth in China, which was up 18% in the third quarter from 10% in the previous quarter, growing domestic competition has caused some to struggle.